In Vitro Synergistic Activity of Ceftazidime-Avibactam and Aztreonam against New Delhi Metallo-β-Lactamase-Producing Clinical Enterobacterales Isolates

Naif Fahd AlAnazi, Mohammad Marie, Ali Mohammad Somily, Khalifa Binkhamis, Muhammad Arshad, Akram A. Alfuraydi, Muhammad Absar

Abstract


Background: Carbapenemase-producing-Enterobacterales (CPE) infections are on the rise and associated with increased morbidity and mortality, due to a limited number of therapeutic options. The goal of this study was to assess the synergistic activity of ceftazidime-avibactam (CZA) and aztreonam (ATM) combination against phenotypically and genetically characterized blaMBL-producing Enterobacterales.

Methods: In this study, forty (n=40) non-repeat, CPE clinical isolates, including: n=35 Klebsiella pneumoniae, n=2 each of Escherichia coli and Klebsiella oxytoca, and n=1 Enterobacter cloacae isolates were identified and susceptibilities were assessed using the Vitek-II compact (bioMérieux, Inc., France) and Microscan Walkaway (Beckman Coulter) systems. Genotypic analysis of clinically relevant carbapenemases was performed by using Xpert-Carba-R assay on GeneXpert (Cepheid, USA). The minimum inhibitory concentrations (MICs) and synergy testing of CZA and ATM, were tested by the Etest fixed ratio method (bioMérieux, Inc., France). The fractional inhibitory concentration index (FICI) was calculated for each antibiotic.

Results: Our results showed that 97.5% of blaMBL-producing Enterobacterales isolates were susceptible to an in-vitro CZA + ATM combination regimen. The fractional inhibitory concentration index (FICI) ranged from 0.001 to 1.001. Among the tested CPE isolates, Synergy was observed in 36/40 (90%), an additive effect was observed in 5% (n=2)’ while two (5%) isolates showed indifference. There was no antagonism observed in our study.

Conclusion: Our study exhibited a potent activity of CZA and ATM combination synergy against clinical CPE metallo- β-lactamase producers. More extensive studies involving a variety of Gram-negative pathogens with different resistance mechanisms are required to determine the efficacy of this combination regimen.

Keywords: Synergy; Aztreonam; Ceftazidime-Avibactam; Carbapenem-Resistant Enterobacterales; Etest 


Full Text:

PDF

References


Jean SS, Gould IM, Lee WS, Hsueh PR. New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship. Drugs, (2019); 79: 705-714.

Wang B, Pan F, Wang C, Zhao W, Sun Y, et al. Molecular epidemiology of Carbapenem-resistant Klebsiella pneumoniae in a paediatric hospital in China. International Journal of Infectious Diseases, (2020); 93: 311-319.

Alotaibi F. Carbapenem-Resistant Enterobacteriaceae: An update narrative review from Saudi Arabia. Journal of Infection and Public Health, (2019); 12(4): 465-471.

Lee CR, Lee JH, Park KS, Kim YB, Jeong BC, et al. Global Dissemination of Carbapenemase-Producing Klebsiella pneumoniae: Epidemiology, Genetic Context, Treatment Options, and Detection Methods. Frontiers in Microbiology, (2016); 7: 895.

Wang Z, Ma K, Chen Z, Guo Z, Zhao G, et al. Successful Treatment of Early Post-Transplant Bloodstream and Pulmonary Infection Caused by Carbapenem-Resistant Klebsiella pneumoniae With a Combination of Ceftazidime-Avibactam and Carbapenem: A Case Report. In Transplantation Proceedings, (2020); 52(9): 2742-2746.

Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. The Lancet Infectious Diseases, (2013); 13(9): 785-796.

Mantilla-Calderon D, Jumat MR, Wang T, Ganesan P, Al-Jassim N, et al. Isolation and Characterization of NDM-Positive Escherichia coli from Municipal Wastewater in Jeddah, Saudi Arabia. Antimicrobial Agents and Chemotherapy, (2016); 60(9): 5223-5231.

Bush K, Jacoby GA. Updated functional classification of β-lactamases. Antimicrobial Agents and Chemotherapy, (2010); 54(3): 969-976.

Bush K. Past and Present Perspectives on β-Lactamases. Antimicrobial Agents and Chemotherapy, (2018); 62(10): e01076-18.

Bush K. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. International Journal of Antimicrobial Agents, (2015); 46(5): 483-493.

Kazmierczak KM, Bradford PA, Stone GG, de Jonge BLM, Sahm DF. In Vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015. Antimicrobial Agents and Chemotherapy, (2018); 62(12): e00592-18.

Davido B, Fellous L, Lawrence C, Maxime V, Rottman M, et al. Ceftazidime-Avibactam and Aztreonam, an Interesting Strategy To Overcome β-Lactam Resistance Conferred by Metallo- β-Lactam resistance conferred by metallo-β-lactamases in Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, (2017); 61(9): e01008-17.

Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Humphries RM, et al. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae? Antimicrobial Agents and Chemotherapy, (2017); 61(4): e02243-16.

Bocanegra-Ibarias P, Camacho-Ortiz A, Garza-González E, Flores-Treviño S, Kim H, et al. Aztreonam plus ceftazidime-avibactam as treatment of NDM-1-producing Klebsiella pneumoniae bacteraemia in a neutropenic patient: Last resort therapy? Journal of Global Antimicrobial Resistance, (2020); 23: 417-419.

Rosa R, Rudin SD, Rojas LJ, Perez-Cardona A, Aragon L, et al. Application of "Precision Medicine" Through the Molecular Characterization of Extensively Drug-Resistant Klebsiella pneumoniae in a Multivisceral Transplant Patient. Clinical Infectious Diseases, (2017); 65(4): 701-702.

Pragasam AK, Veeraraghavan B, Shankar BA, Bakthavatchalam YD, Mathuram A, et al. Will ceftazidime/avibactam plus aztreonam be effective for NDM and OXA-48-Like producing organisms: Lessons learnt from In vitro study. Indian journal of medical microbiology, (2019); 37(1): 34-41.

Zhang W, Guo Y, Li J, Zhang Y, Yang Y, et al. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing Klebsiella pneumoniae. Antimicrobial Resistance and Infection Control, (2018); 7: 142.

Emeraud C, Escaut L, Boucly A, Fortineau N, Bonnin RA, et al. Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria. Antimicrobial Agents and Chemotherapy, (2019); 63(5): e00010-19.

Wayne PA. Performance standards for antimicrobial susceptibility testing 30th ed. 2020; 294. Clinical and Laboratory Standards Institute

Logan LK, Bonomo RA. Metallo-β-Lactamase (MBL)-Producing Enterobacteriaceae in United States Children. In Open forum infectious diseases. (2016); 3(2): ofw090.

Padhi S. New Delhi metallo-beta-lactamase: a weapon for the newly emerging drug-resistant bacteria. Indian Journal of Medical Sciences, (2011); 65(8): 317-320.

Balkhy HH, El-Saed A, Alshamrani MM, Alsaedi A, Al Nasser W, et al. Ten-year resistance trends in pathogens causing healthcare-associated infections; reflection of infection control interventions at a multi-hospital healthcare system in Saudi Arabia, 2007-2016. Antimicrobial Resistance and Infection Control, (2020); 9(1): 1-12.

Alghoribi MF, Binkhamis K, Alswaji AA, Alhijji A, Alsharidi A, et al. Genomic analysis of the first KPC-producing Klebsiella pneumoniae isolated from a patient in Riyadh: A new public health concern in Saudi Arabia. Journal of Infection and Public Health, (2020); 13(4): 647-650.

Hala S, Antony CP, Alshehri M, Althaqafi AO, Alsaedi A, et al. First report of Klebsiella quasipneumoniae harboring bla (KPC-2) in Saudi Arabia. Antimicrobial Resistance and Infection Control, (2019); 8: 1-8.

van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence, (2017); 8(4): 460-469.

Karakonstantis S, Kritsotakis EI, Gikas A. Pandrug-resistant Gram-negative bacteria: a systematic review of current epidemiology, prognosis and treatment options. Journal of Antimicrobial Chemotherapy, (2020); 75(2): 271-282.

Falcone M, Daikos GL, Tiseo G, Bassoulis D, Giordano C, et al. Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales. Clinical infectious diseases, (2021); 72(11): 1871-1878.

Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, et al. Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clinical infectious diseases, (2023); ciad428.

de Jonge BL, Karlowsky JA, Kazmierczak KM, Biedenbach DJ, Sahm DF, et al. In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014). Antimicrobial Agents and Chemotherapy, (2016); 60(5): 3163-3169.

Li H, Estabrook M, Jacoby GA, Nichols WW, Testa RT, et al. In vitro susceptibility of characterized β-lactamase-producing strains tested with avibactam combinations. Antimicrobial Agents and Chemotherapy, (2015); 59(3): 1789-1793.

Gomez-Simmonds A, Nelson B, Eiras DP, Loo A, Jenkins SG, et al. Combination Regimens for Treatment of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections. Antimicrobial Agents and Chemotherapy, (2016); 60(6): 3601-3607.

Hellmark B, Unemo M, Nilsdotter-Augustinsson A, Söderquist B. In vitro antimicrobial synergy testing of coagulase-negative staphylococci isolated from prosthetic joint infections using Etest and with a focus on rifampicin and linezolid. European Journal of Clinical Microbiology & Infectious Diseases, (2010); 29: 591-595.

Wenzler E, Deraedt MF, Harrington AT, Danizger LH. Synergistic activity of ceftazidime-avibactam and aztreonam against serine and metallo-β-lactamase-producing gram-negative pathogens. Diagnostic Microbiology and Infectious Disease , (2017); 88(4): 352-354.




DOI: http://dx.doi.org/10.62940/als.v11i4.3297

Refbacks

  • There are currently no refbacks.